Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 294.00
Bid: 292.00
Ask: 298.00
Change: -3.00 (-1.01%)
Spread: 6.00 (2.055%)
Open: 294.00
High: 294.00
Low: 294.00
Prev. Close: 298.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

2 Jul 2021 09:30

RNS Number : 9844D
Hutchmed (China) Limited
02 July 2021
 

HUTCHMED to Announce 2021 Half-Year Financial Results

 

Hong Kong, Shanghai & Florham Park, NJ - Friday, July 2, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2021 on Wednesday, July 28, 2021 at 12:00 noon British Summer Time (BST) (7:00 pm Hong Kong Time (HKT); 7:00 am Eastern Daylight Time (EDT)).

 

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

 

The conference call and audio webcast will take place at 1:00 pm BST / 8:00 pm HKT / 8:00 am EDT on Wednesday, July 28, 2021 and will be webcast live via the company website at www.hutch-med.com/investors/event-information/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM; SEHK: 13) (formerly Hutchison China MediTech) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

 

 

CONTACTS

 

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)HUTCHMED@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile) / +852 9783 6894 (Mobile)

HUTCHMED@brunswickgroup.com

Nominated Advisor

Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORQLLBBFDLFBBB
Date   Source Headline
22nd Jul 20117:00 amRNSChina Healthcare Division expansion
5th Jul 20117:00 amRNSNotice of Results
29th Jun 20117:00 amRNSBlocklisting Interim Review
13th May 20118:25 amRNSHolding(s) in Company
9th May 20111:18 pmRNSResult of AGM
9th May 20117:00 amRNSHolding(s) in Company
4th Apr 20117:00 amRNS2010 Annual Report and Notice of AGM
28th Mar 201112:28 pmRNSDirector/PDMR Shareholding
9th Mar 20117:00 amRNSFinal Results
21st Feb 20117:00 amRNSBoard Change
15th Feb 20117:00 amRNSAppointment of UBS Limited as Joint Broker
1st Feb 20117:00 amRNSFruquintinib starts Phase I cancer clinical trial
31st Jan 20119:00 amRNSNotice of Results
5th Jan 20119:00 amRNSTotal Voting Rights
29th Dec 20109:00 amRNSBlocklisting Interim Review
21st Dec 20107:00 amRNSSBCVC Investment in MediPharma
10th Dec 20107:00 amRNSIncreases indirect ownership of OTC joint venture
8th Nov 20107:00 amRNSHutchison MediPharma Receives Strategic Investment
20th Sep 20107:00 amRNSOrganic Infant formula launched in China
15th Sep 20107:00 amRNSAppointment of Joint Broker
29th Jul 20107:00 amRNSInterim Results
14th Jul 20109:18 amRNSHolding(s) in Company
7th Jul 20109:26 amRNSHolding(s) in Company
7th Jul 20107:00 amRNSNotice of Results
5th Jul 20108:58 amRNSTotal Voting Rights
29th Jun 20101:59 pmRNSBlocklisting Six Monthly Return
25th Jun 20109:50 amRNSDirector/PDMR Shareholding
17th Jun 20109:01 amRNSHolding(s) in Company
30th Apr 20101:18 pmRNSResult of AGM
30th Apr 20107:00 amRNSPhase I Trial of Sulfatinib for Cancer Initiated
19th Apr 20107:00 amRNSIP protection for main prescription drug extended
29th Mar 20107:00 amRNS2009 Annual Report and Notice of AGM
15th Mar 20109:15 amRNSHolding(s) in Company
12th Mar 20109:40 amRNSHolding(s) in Company
10th Mar 201010:47 amRNSHolding(s) in Company
8th Mar 20109:13 amRNSHolding(s) in Company
4th Mar 20107:00 amRNSFinal Results
8th Feb 20109:00 amRNSNotice of Results
2nd Feb 201011:24 amRNSTotal Voting Rights
19th Jan 20107:00 amRNSMore drugs added to Chinese Medicines Catalogue
4th Jan 20109:20 amRNSTotal Voting Rights
29th Dec 20099:05 amRNSBlocklisting Interim Review
26th Nov 20097:00 amRNSHolding(s) in Company
5th Nov 200910:23 amRNSSuccessful Phase IIb UC Trial for HMPL-004
30th Oct 20097:00 amRNSInitiates Phase I Clinical Trial of HMPL-011
26th Oct 20097:00 amRNSAcquires 100% of Hutchison Healthcare JV
16th Oct 20097:00 amRNSStatement on Essential Medicines List
8th Oct 20097:00 amRNSJoint venture with The Hain Celestial Group
27th Aug 20097:00 amRNSKey Drugs in New National Essential Medicines List
30th Jul 20097:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.